APA (7th ed.) Citation

K, C., M, L., G, T., I, G., & A, C. (2021). Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift? Clinical rheumatology, 40(5), 1687. https://doi.org/10.1007/s10067-020-05420-w

Chicago Style (17th ed.) Citation

K, Chatzidionysiou, Liapi M, Tsakonas G, Gunnarsson I, and Catrina A. "Treatment of Rheumatic Immune-related Adverse Events Due to Cancer Immunotherapy with Immune Checkpoint Inhibitors-is It Time for a Paradigm Shift?" Clinical Rheumatology 40, no. 5 (2021): 1687. https://doi.org/10.1007/s10067-020-05420-w.

MLA (9th ed.) Citation

K, Chatzidionysiou, et al. "Treatment of Rheumatic Immune-related Adverse Events Due to Cancer Immunotherapy with Immune Checkpoint Inhibitors-is It Time for a Paradigm Shift?" Clinical Rheumatology, vol. 40, no. 5, 2021, p. 1687, https://doi.org/10.1007/s10067-020-05420-w.